MorphoSys Completes Sale of AbD Serotec to Bio-Rad
News Jan 11, 2013
MorphoSys AG has announced that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. has been completed.
All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.
"We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," commented Jens Holstein, Chief Financial Officer of MorphoSys AG.
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
The Role of Lung Cell Turnover in Influenza PneumoniaNews
Research led by University of Cincinnati scientists is investigating how influenza spreads through the lungs by focusing on how resistant or susceptible cells lining the airway are to viral infection.READ MORE
LifeArc Becomes Technology Transfer Partner to London School of Hygiene & Tropical MedicineNews
LifeArc, the medical research charity, has partnered with London School of Hygiene & Tropical Medicine to provide a range of services in technology transfers.READ MORE